U.S. FDA Says Chinese Supplier Of Heparin API Never Inspected
This article was originally published in PharmAsia News
The U.S. FDA blames human error and other problems for never inspecting the facilities of a Chinese supplier of active ingredients contained in Baxter International's heparin product. The product has been linked to four deaths and hundreds of allergic reactions. An FDA spokeswoman said the agency inspected the Baxter facility in New Jersey where the finished version of the drug was made, but because of a series of errors, the Chinese plant was never inspected. She said the agency is preparing to inspect the Chinese facility, which was not identified, as soon as possible. (Click here for more - a subscription may be required
You may also be interested in...
A key House subcommittee chairman has called for the resignation of U.S. FDA Commissioner Andrew von Eschenbach in the wake of reports that FDA failed to inspect a Chinese API manufacturer that may be linked to adverse reactions in patients taking injectable heparin, a blood thinner marketed by Baxter Healthcare (PharmAsia News, Feb. 14, 2008)
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs